Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 28 2024 - 6:10PM
Business Wire
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”),
an innovative biopharmaceutical company developing miniature, ultra
long-acting, subdermal drug implants, today announced its plans to
participate in the H.C. Wainwright 26th Annual Global Investment
Conference taking place September 9-11, 2024 in New York, New
York.
Vivani’s Chief Executive Officer, Adam Mendelsohn, Ph.D., will
host one-on-one meetings with investors at the Conference in
addition to providing an overview of the Company. Details of this
presentation are as follows:
Date: Wednesday, September 11, 2024 Time: 10-10:30
a.m. Eastern Time Location: Adams Room (Fourth floor), Lotte
New York Palace, New York, NY
The Company presentation will be available via webcast starting
at 10 a.m. ET on September 11 at the following link:
https://journey.ct.events/view/a00c80c3-0668-4058-b4ca-4aad48978600.
The presentation will also be available on the Company’s website
under the “News & Events” tab of the Vivani Investor page:
https://investors.vivani.com/investors/news-events.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops
biopharmaceutical implants designed to deliver drug molecules
steadily over extended periods of time with the goal of
guaranteeing adherence, and potentially to improve tolerance to
their medication. Vivani’s lead program, NPM-115, will evaluate a
miniature, six-month, subdermal, GLP-1 (exenatide) implant for
chronic weight management in obese or overweight patients. Vivani’s
emerging pipeline also includes NPM-139 (semaglutide implant) which
is also under development for chronic weight management in obese
and overweight patients. NPM-139 has the added potential benefit of
once-yearly administration. NPM-119 refers to the Company’s
clinical program which will evaluate its six-month, subdermal
exenatide implant for the treatment of type 2 diabetes. Both
NPM-115 and NPM-119 will evaluate exenatide implants with a
higher-dose associated with NPM-115 for chronic weight management
in obese or overweight patients. These NanoPortal implants are
designed to provide patients with the opportunity to realize the
full potential benefit of their medication by avoiding the
challenges associated with the daily or weekly administration of
orals and injectables. Medication non-adherence occurs when
patients do not take their medication as prescribed. This affects
an alarming number of patients, approximately 50%, including those
taking daily pills. Medication non-adherence, which contributes to
more than $500 billion in annual avoidable healthcare costs and
125,000 potentially preventable deaths annually in the U.S. alone,
is a primary and daunting reason obese or overweight patients, and
patients taking type 2 diabetes or other chronic disease treatments
face significant challenges in achieving positive real-world
effectiveness. While the current GLP-1 landscape includes over 50
new molecular entities under clinical stage development, Vivani
remains confident that its highly differentiated portfolio of
miniature long-acting GLP-1 implants have the potential to provide
an attractive therapeutic option for patients, prescribers and
payers.
Forward-Looking Statements
This press release contains certain “forward-looking statements”
within the meaning of the “safe harbor” provisions of the US
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “target,” “believe,”
“expect,” “will,” “may,” “anticipate,” “estimate,” “would,”
“positioned,” “future,” and other similar expressions that in this
press release, including statements regarding Vivani’s business,
products in development, including the therapeutic potential
thereof, the planned development therefor, the initiation of the
LIBERATE-1 trial and reporting of trial results, Vivani’s emerging
development plans for NPM-115, NPM-139, and NPM-119.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
Vivani’s current beliefs, expectations, and assumptions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of Vivani’s
control. Actual results and outcomes may differ materially from
those indicated in the forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements.
Important factors that could cause actual results and outcomes to
differ materially from those indicated in the forward-looking
statements include, among others, risks related to the development
and commercialization of Vivani’s products, including NPM-115,
NPM-139, and NPM-119; delays and changes in the development of
Vivani’s products, including as a result of applicable laws,
regulations and guidelines, potential delays in submitting and
receiving regulatory clearance or approval to conduct Vivani’s
development activities, including Vivani’s ability to commence
clinical development of NPM-115; risks related to the initiation,
enrollment and conduct of Vivani’s planned clinical trials and the
results therefrom; Vivani’s history of losses and Vivani’s ability
to access additional capital or otherwise fund Vivani’s business.
There may be additional risks that the Company considers
immaterial, or which are unknown. A further list and description of
risks and uncertainties can be found in the Company’s most recent
Annual Report on Form 10-K filed with the U.S. Securities and
Exchange Commission filed on March 26, 2024, as updated by the
Company’s subsequent Quarterly Reports on Form 10-Q. Any
forward-looking statement made by Vivani in this press release is
based only on information currently available to the Company and
speaks only as of the date on which it is made. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of added information, future developments
or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240828761016/en/
Company Contact: Donald Dwyer Chief Business Officer
info@vivani.com (415) 506-8462 Investor Relations Contact: Jami
Taylor Investor Relations Advisor investors@vivani.com (415)
506-8462 Media Contact: Sean Leous ICR Westwicke
sean.leous@westwicke.com (646) 866-4012
Vivani Medical (NASDAQ:VANI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Vivani Medical (NASDAQ:VANI)
Historical Stock Chart
From Aug 2023 to Aug 2024